Among other treatments, the efficacy of daclizumab, a monoclonal antibody against the IL-2R-α (CD25), combined with depsipeptide, a member of the cyclic peptide class of HDAC inhibitors, was tested by analyzing the survival of the leukemia-bearing mice and the levels of soluble IL-2R-α and β2μ levels. The gene discussed is IL2RA; the disease is leukemia.